Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
JAK2 mutation
i
Other names:
JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3717
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
JAK2 amplification (2)
JAK2 deletion (1)
JAK2 amplification (2)
JAK2 deletion (1)
›
Associations
(4)
News
Trials
Search handles
@AaronGoodman33
@Anand_88_Patel
@DavidSteensma
@NitinJainMD
@TaylorJ_MD
@akeithstewart
@doctorpemm
@hemedoc
@n_gangat
@smbenlazar
Search handles
@AaronGoodman33
@Anand_88_Patel
@DavidSteensma
@NitinJainMD
@TaylorJ_MD
@akeithstewart
@doctorpemm
@hemedoc
@n_gangat
@smbenlazar
Filter by
Latest
1year
JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management #mpnsm https://t.co/SOe1dQAhzG (@smbenlazar)
1 year ago
JAK2 (Janus kinase 2)
|
JAK2 mutation
1year
Monday reading for the vexing erythrocytosis consult JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management https://t.co/v3PRBOqSEN #mpnsm @NatashaSzuber #tefferi @MayoCancerCare @AjHematology (@n_gangat)
1 year ago
JAK2 (Janus kinase 2)
|
JAK2 mutation
1year
PRV Jak-2 mutation Acute Leukemia (@iSuksBlood)
1 year ago
JAK2 (Janus kinase 2)
|
JAK2 mutation
1year
Polycythemia vera/PV Increased platelet count, JAK2 67F mutation, AML (@suefreelance)
1 year ago
JAK2 (Janus kinase 2)
|
JAK2 mutation
almost2years
This is cool! Polycythemia + Eosinophilia associated with novel JAK2 mutation = JAK2ex13InDel Add this to my differential! JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera https://t.co/eonM3YsPnt (@AaronGoodman33)
almost 2 years ago
JAK2 (Janus kinase 2)
|
JAK2 mutation
almost2years
#ASCO22 #leusm Menghrajani: Why aren’t JAKi the new imatinib in JAK2 mutated MPN? JAK-STAT may not be only pathway involved. Adding BCL2i to Rux shows promising results. (@hemedoc)
almost 2 years ago
JAK2 (Janus kinase 2)
|
JAK2 mutation
|
imatinib
2years
Very interesting @BloodJournal paper from @RaajitRampal et al looking at leukemic transformation in JAK2/TP53-mutated megakaryocyte/erythroid precursors #mpnsm #leusm https://t.co/zUHhGukRmM (@Anand_88_Patel)
2 years ago
TP53 (Tumor protein P53) • JAK2 (Janus kinase 2)
|
TP53 mutation • JAK2 mutation
2years
We also report the first patients with PV in whom JAK2 mutation became undetectable after 5 years of #ropeginterferon therapy (5 patients) vs. none with standard treatment, a prerequisite for changing #mpnsm disease natural evolution @LeukemiaJnl 👇 https://t.co/PelUXPZaXp (@jjkiladjian)
2 years ago
Clinical
|
JAK2 (Janus kinase 2)
|
JAK2 mutation
2years
Happy to share the 5-years results of the PROUD-CONTI PV study confirming the long-term safety and efficacy of #ropeginterferon and the clear superiority for deeply reducing the JAK2 mutation burden compared to standard therapy @LeukemiaJnl #mpnsm 👉 https://t.co/C5z59aOi5H (@jjkiladjian)
2 years ago
Clinical • Head-to-Head
|
TMB (Tumor Mutational Burden) • JAK2 (Janus kinase 2)
|
JAK2 mutation
over2years
Great summary! @AaronGoodman33 One addition for JAK2 mutation JAK2 R683G = Ph-like ALL (~50% of CRLF2 rearranged ALL, a subset of Ph-like ALL have JAK2 mutation, most commonly R683G, never V617F) And yes JAK fusions can also occur in Ph-like ALL #leusm (@NitinJainMD)
over 2 years ago
JAK2 (Janus kinase 2) • CRLF2 (Cytokine Receptor Like Factor 2)
|
CRLF2 rearrangement • JAK2 V617F • JAK2 mutation • JAK2 R683G
over2years
Trial in progress: anti-SLAMF7 elotuzumab in JAK2-mutated myelofibrosis w/ @bose_prithviraj of @MDAndersonNews Watch: 👉https://t.co/A7PG0wSgcn👈 #ASH21 @ASH_hematology #HemOnc #LymSM #LeuSM #MMsm (@VJHemOnc)
over 2 years ago
IO biomarker
|
JAK2 (Janus kinase 2)
|
JAK2 mutation
|
Empliciti (elotuzumab)
over2years
#ASH21 #MPNSM Oral session #6. Dr Bing Li @RaajitRampal @rosslevinemd | Wonderful, high-impact work: #BMP2 #SMAD pathway activation in #JAK2/#TP53 mutant MEPs promotes leukemic transformation || #MPNSM #leusm #ASHKudos 👏🏽 (@doctorpemm)
over 2 years ago
TP53 (Tumor protein P53) • JAK2 (Janus kinase 2)
|
TP53 mutation • JAK2 mutation
almost3years
Question for #myeloma community - would u start rev maintenance post asct in someone with positive jak2 mutation in peripheral blood mncs - normal counts @TomBmt133 @SagarLonialMD @Rfonsi1 @szusmani @NBahlis @DrOlaLandgren @DrGarethMorgan1 @VincentRK (@akeithstewart)
almost 3 years ago
Clinical
|
JAK2 (Janus kinase 2)
|
JAK2 mutation
3years
Very important project leaded by A. Alvarez Larran: should CALR-mutated ET be managed differently than JAK2-mutated? A new #ELN #EuropeanLeukemiaNet project #mpnsm (@jjkiladjian)
3 years ago
JAK2 (Janus kinase 2) • CALR (Calreticulin)
|
JAK2 mutation • CALR mutation
over3years
We knew from work of Sir Mel Greaves & colleagues that initiating mutations in childhood leukemias often occur in utero, even outside Down syndrome setting. But to develop an MPN at age 54 from a somatic JAK2 mutation that occurred before age 1 is really extraordinary. /2 #ASH20 (@DavidSteensma)
over 3 years ago
Clinical
|
JAK2 (Janus kinase 2)
|
JAK2 mutation
over3years
#ASH20 I agree this was very nice work! And important to stress AND the measurement of growth rate. It is well known JAK2 V617F mutations can occur years before diagnosis so early detection alone is not enough. #MPNsm #leusm (@TaylorJ_MD)
over 3 years ago
JAK2 (Janus kinase 2)
|
JAK2 V617F • JAK2 mutation
over3years
Please experts, help me... are there hematological malignancies where reducing the driver mutation is not clinically beneficial? I'm confused, this is disputed for PV and JAK2 mutation, so finding another example could be helpful... I can also take examples in solid tumors... (@jjkiladjian)
over 3 years ago
Clinical
|
JAK2 (Janus kinase 2)
|
JAK2 mutation
almost4years
Very interesting, this table by @peters_solange. I just think that B2M and JAK2 mutations need to be considered in NSCLC. Not that rare! Maybe about 10 percent (@CespedesMontse)
almost 4 years ago
JAK2 (Janus kinase 2) • B2M (Beta-2-microglobulin)
|
JAK2 mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login